Women live longer than men: Understanding molecular mechanisms offers opportunities to intervene by using estrogenic compounds

Antioxidants and Redox Signaling

Volumn 13, Issue 3, 2010, Pages 269-278

  Viña, Jose ^a   Borrás, Consuelo ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUTATHIONE PEROXIDASE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; PHYTOESTROGEN; RALOXIFENE; REACTIVE OXYGEN METABOLITE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ANTIOXIDANT; FREE RADICAL;

AGING; ANTIOXIDANT ACTIVITY; DIET THERAPY; ELECTRON SPIN RESONANCE; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; HUMAN; LIFE EXPECTANCY; LIFESPAN; LONGEVITY; MENOPAUSAL SYNDROME; MOLECULAR MECHANICS; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEX DIFFERENCE; UPREGULATION; ANIMAL; DRUG EFFECTS; FEMALE; MALE; METABOLISM; PHYSIOLOGY;

ANIMALIA;

AGING; ANIMALS; ANTIOXIDANTS; ESTROGENS; FEMALE; FREE RADICALS; HUMANS; LIFE EXPECTANCY; LONGEVITY; MALE; OXIDATIVE STRESS; PHYTOESTROGENS; SEX FACTORS;

EID: 77954092125     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2952     Document Type: Review

References (68)

1. Update on estrogens and uterine cancer. FDA Drug Bull 9: 2-3, 1979.
2. Ali SS, Xiong C, Lucero J, Behrens MM, Dugan LL, and Quick KL. Gender differences in free radical homeostasis during aging: Shorter-lived female C57BL6 mice have increased oxidative stress. Aging Cell 5: 565-574, 2006.
3. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, and Leitman DC. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 276: 17808-17814, 2001.
4. Arias E. United States life tables, 2004. Natl Vital Stat Rep 56: 1-39, 2007.
5. Artandi SE, Alson S, Tietze MK, Sharpless NE, Ye S, Greenberg RA, Castrillon DH, Horner JW, Weiler SR, Car-rasco RD, and DePinho RA. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci USA 99: 8191-8196, 2002.
6. Austad SN. Why women live longer than men: Sex differences in longevity. Gend Med 3: 79-92, 2006.
7. Borras C, Esteve JM, Vina JR, Sastre J, Vina J, and Pallardo FV. Glutathione regulates telomerase activity in 3T3 fibro-blasts. J Biol Chem 279: 34332-34335, 2004.
8. Borras C, Gambini J, Gomez-Cabrera MC, Sastre J, Pallardo FV, Mann GE, and Vina J. 17beta-oestradiol up-regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK2[MAPK]=NFkappaB cascade. Aging Cell 4: 113-118, 2005.
9. Borras C, Gambini J, Gomez-Cabrera MC, Sastre J, Pallardo FV, Mann GE, and Vina J. Genistein, a soy isoflavone, up-regulates expression of antioxidant genes: involvement of estrogen receptors, ERK1=2, and NFkappaB. FASEB J 20: 2136-2138, 2006.
10. Borras C, Sastre J, Garcia-Sala D, Lloret A, Pallardo FV, and Vina J. Mitochondria from females exhibit higher antioxi-dant gene expression and lower oxidative damage than males. Free Radic Biol Med 34: 546-552, 2003.
11. Budanov AV, Sablina AA, Feinstein E, Koonin EV, and Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304: 596-600, 2004.
12. Candore G, Balistreri CR, Listi F, Grimaldi MP, Vasto S, Colonna-Romano G, Franceschi C, Lio D, Caselli G, and Caruso C. Immunogenetics, gender, and longevity. Ann NY Acad Sci 1089: 516-537, 2006.
13. Cargill SL, Carey JR, Muller HG, and Anderson G. Age of ovary determines remaining life expectancy in old ovariec-tomized mice. Aging Cell 2: 185-190, 2003.
14. Cassidy A, Brown JE, Hawdon A, Faughnan MS, King LJ, Millward J, Zimmer-Nechemias L, Wolfe B, and Setchell KD. Factors affecting the bioavailability of soy isoflavones in humans after ingestion of physiologically relevant levels from different soy foods. J Nutr 136: 45-51, 2006.
15. Coe JE, Ishak KG, Ward JM, and Ross MJ. Tamoxifen prevents induction of hepatic neoplasia by zeranol, an es-trogenic food contaminant. Proc Natl Acad Sci USA 89: 1085-1089, 1992.
16. Christensen K, Doblhammer G, Rau R, and Vaupel JW. Aging populations: The challenges ahead. Lancet 374: 1196-1208, 2009.
17. Davis P, Graham P, and Pearce N. Health expectancy in New Zealand, 1981-1991: Social variations and trends in a period of rapid social and economic change. J Epidemiol Community Health 53: 519-527, 1999.
18. Dhandapani KM and Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 67: 1379-1385, 2002.
19. Emslie C, Hunt K, and Macintyre S. How similar are the smoking and drinking habits of men and women in non-manual jobs? Eur J Public Health 12: 22-28, 2002.
20. Ettinger B, Friedman GD, Bush T, and Quesenberry CP, Jr. Reduced mortality associated with long-term postmeno-pausal estrogen therapy. Obstet Gynecol 87: 6-12, 1996.
21. Fernandez Ballesteros R. Aging in Europe\European Aging. IVth European Congress of Gerontology. Berlin, Germany, July 7-11, 1999. Abstracts. Z Gerontol Geriatr 32: II1-298, 299-312, 1999.
22. Finkel T, Deng CX, and MostoslavskyR.Recent progressinthe biology and physiology of sirtuins. Nature 460: 587-591, 2009.
23. Fournier A, Mesrine S, Boutron-Ruault MC, and Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast Ccancer: Does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 27: 5138-5143, 2009.
24. Fox CW, Scheibly KL, Wallin WG, Hitchcock LJ, Stillwell RC, and Smith BP. The genetic architecture of life span and mortality rates: Gender and species differences in inbreeding load of two seed-feeding beetles. Genetics 174: 763-773, 2006.
25. Gill TM, Baker DI, Gottschalk M, Peduzzi PN, Allore H, and Byers A. A program to prevent functional decline in physically frail, elderly persons who live at home. N Engl J Med 347: 1068-1074, 2002.
26. Gold SM and Voskuhl RR. Estrogen treatment in multiple sclerosis. J Neurol Sci 286: 99-103, 2009.
27. Gomez-Cabrera MC, Borras C, Pallardo FV, Sastre J, Ji LL, and Vina J. Decreasing xanthine oxidase-mediated oxidative stress prevents useful cellular adaptations to exercise in rats. J Physiol 567: 113-120, 2005.
28. Gomez-Cabrera MC, Domenech E, and Vina J. Moderate exercise is an antioxidant: Upregulation of antioxidant genes by training. Free Radic Biol Med 44: 126-131, 2008.
29. Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 72: 483-488, 2007.
30. Halliwell B and Gutteridge JM. The definition and measurement of antioxidants in biological systems. Free Radic Biol Med 18: 125-126, 1995.
31. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, McCleary CA, Klein RA, Hake AM, and Farlow MR. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology 54: 295-301, 2000.
32. Hilakivi-Clarke L, Cabanes A, Olivo S, Kerr L, Bouker KB, and Clarke R. Do estrogens always increase breast cancer risk? J Steroid Biochem Mol Biol 80: 163-174, 2002.
33. Howell A, Howell SJ, Clarke R, and Anderson E. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol 79: 227-237, 2001.
34. Jang YM, Kendaiah S, Drew B, Phillips T, Selman C, Julian D, and Leeuwenburgh C. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett 577: 483-490, 2004.
35. Johnston SR. Acquired tamoxifen resistance in human breast cancer\Potential mechanisms and clinical implications. Anticancer Drugs 8: 911-930, 1997.
36. Kaiser J. Endocrine disrupters. Controversy continues after panel rules on bisphenol A. Science 317: 884-885, 2007.
37. Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, Axelsson CK, Gronholdt ML, Grande P, Jensen GB, and Nordestgaard BG. Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: Cross-sectional, cohort, and case-control studies and a meta-analysis. Circulation 115: 861-871, 2007.
38. Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, Orimo A, and Inoue M. Estrogen activates telomerase. Cancer Res 59: 5917-5921, 1999.
39. La Vecchia C. Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer. Breast 13: 515-518, 2004.
40. Leung FP, Tsang SY, Wong CM, Yung LM, Chan YC, Leung HS, Yao X, and Huang Y. Raloxifene, tamoxifen and vascular tone. Clin Exp Pharmacol Physiol 34: 809-813, 2007.
41. Lewis-Wambi JS and Jordan VC. Treatment of postmeno-pausal breast cancer with selective estrogen receptor modulators (SERMs). Breast Dis 24: 93-105, 2005.
42. Macilwain C. US panel split on endocrine disruptors. Nature 395: 828, 1998.
43. Mahn K, Borras C, Knock GA, Taylor P, Khan IY, Sugden D, Poston L, Ward JP, Sharpe RM, Vina J, Aaronson PI, and Mann GE. Dietary soy isoflavone induced increases in an-tioxidant and eNOS gene expression lead to improved en-dothelial function and reduced blood pressure in vivo. FASEB J 19: 1755-1757, 2005.
44. Maklakov AA, Fricke C, and Arnqvist G. Sexual selection affects lifespan and aging in the seed beetle. Aging Cell 6: 739-744, 2007.
45. Marchesoni D, Gangemi M, Di Lenardo L, Mozzanega B, and Valente S. Estrogen therapy in menopause and endometrial cancer. Clin Exp Obstet Gynecol 7: 122-125, 1980.
46. Mason JB, Cargill SL, Anderson GB, and Carey JR. Transplantation of young ovaries to old mice increased life span in transplant recipients. J Gerontol A Biol Sci Med Sci 64: 1207-1211, 2009.
47. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, Flores JM, Vina J, Blasco MA, and Serrano M. Delayed aging through damage protection by the Arf=p53 pathway. Nature 448: 375-379, 2007.
48. Musicco M. Gender differences in the occurrence of Alzheimer's disease. Funct Neurol 24: 89-92, 2009.
49. Navarro A, Gomez C, Lopez-Cepero JM, and Boveris A. Beneficial effects of moderate exercise on mice aging: Survival, behavior, oxidative stress, and mitochondrial electron transfer. Am J Physiol Regul Integr Comp Physiol 286: R505-11, 2004.
50. Olubuyide IO and Ola OS. Clinical feminisation and sex hormone concentrations in Nigerian men with cirrhosis with and without hepatocellular carcinoma. Br J Clin Pract 48: 70-72, 1994.
51. Orr WC and Sohal RS. Extension of life-span by over-expression of superoxide dismutase and catalase in Droso-phila melanogaster. Science 263: 1128-1130, 1994.
52. Osborne CK, Schiff R, Fuqua SA, and Shou J. Estrogen receptor: Current understanding of its activation and modulation. Clin Cancer Res 7: 4338s-4342s; discussion 4411s-4412s, 2001.
53. Paganini-Hill A, Corrada MM, and Kawas CH. Increased longevity in older users of postmenopausal estrogen therapy: The Leisure World Cohort Study. Menopause 13: 12-18, 2006.
54. Park HJ, Della-Fera MA, Hausman DB, Rayalam S, Ambati S, and Baile CA. Genistein inhibits differentiation of primary human adipocytes. J Nutr Biochem 20: 140-148, 2009.
55. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Koo-perberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmeno-pausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
56. Ryan J, Scali J, Carriere I, Ritchie K, and Ancelin ML. Hormonal treatment, mild cognitive impairment and Alzheimer's disease. Int Psychogeriatr 20: 47-56, 2008.
57. Sanz A, Hiona A, Kujoth GC, Seo AY, Hofer T, Kou-wenhoven E, Kalani R, Prolla TA, Barja G, and Leeu-wenburgh C. Evaluation of sex differences on mitochondrial bioenergetics and apoptosis in mice. Exp Gerontol 42: 173-182, 2007.
58. Schiff R, Chamness GC, and Brown PH. Advances in breast cancer treatment and prevention: Preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res 5: 228-231, 2003.
59. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, and Heubi JE. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131: 1362S-1375S, 2001.
60. Setchell KD and Cassidy A. Dietary isoflavones: Biological effects and relevance to human health. J Nutr 129: 758S-767S, 1999.
61. Sinclair DA and Guarente L. Unlocking the secrets of longevity genes. Sci Am 294: 48-51, 54-57, 2006.
62. Sohrabji F. Guarding the blood-brain barrier: A role for estrogen in the etiology of neurodegenerative disease. Gene Expr 13: 311-319, 2007.
63. Swaby RF, Sharma CG, and Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 8: 229-239, 2007.
64. Tomas-Loba A, Flores I, Fernandez-Marcos PJ, Cayuela ML, Maraver A, Tejera A, Borras C, Matheu A, Klatt P, Flores JM, Vina J, Serrano M, and Blasco MA. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 135: 609-622, 2008.
65. Vina J, Sastre J, Pallardo F, and Borras C. Mitochond-rial theory of aging: Importance to explain why females live longer than males. Antioxid Redox Signal 5: 549-556, 2003.
66. Waldron I and Johnston S. Why do women live longer than men? J Human Stress 2: 19-30, 1976. (Pubitemid 8004445)
67. Wilmoth JR, Deegan LJ, Lundstrom H, and Horiuchi S. Increase of maximum life-span in Sweden, 1861-1999. Science 289: 2366-2368, 2000.
68. Zhao L and Brinton RD. Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: Implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease. BMC Neurosci 7: 24, 2006.